Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Diabetic Kidney Disease (DKD) Who Are Receiving Irbesartan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Irbesartan/propagermanium (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms ACTION
- Sponsors Dimerix Bioscience
- 28 Jul 2022 Status changed from active, no longer recruiting to completed.
- 04 Feb 2020 Planned End Date changed from 1 Oct 2019 to 1 Jul 2020.
- 04 Feb 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Jul 2020.